Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) (GHAT)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Johann Wolfgang Goethe University Hospitals.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT01052623
First received: January 19, 2010
Last updated: July 2, 2010
Last verified: July 2010

January 19, 2010
July 2, 2010
January 2010
December 2011   (final data collection date for primary outcome measure)
To evaluate the GH increase after Arginine Provocation Test [ Time Frame: at minute 0, 30, 60, 90 und 120 after infusion ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01052623 on ClinicalTrials.gov Archive Site
The GH increase after Clonidine Provocation Test. To evaluate the safety and efficacy of the IGF-1 generation test. To correlate GH/IgF-1 deficiency to BMI To correlate GH/IgF-1 deficiency to MRI findings [ Time Frame: at minute 0, 30, 60, 90 und 120 after dosing of Clonidin. IgF-1 generation test after 5 days. ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia

This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT).

Growth failure and GH/IgF-1 deficiency has been described in patients diagnosed with Ataxia telangiectasia (AT) [Boder et al.,1958]. This condition is a fatal inherited disease caused by a mutation of the ATM gene on chromosome 11 leading to chromosomal instability, immunodeficiency, cancer susceptibility and and endocrinological abnormalities. In this regard, several groups demonstrated a cross-linking of ATM with growth factor pathways. Participation of the ATM protein in insulin signaling through phosphorylation of eIF-4E-binding protein 1 has been postulated [Yang et al.,2000]. Peretz et al.[2001] described that expression of the insulin-like growth factor-I receptor is (IGF-I R) ATM dependent in a pathway regulating radiation response. In addition, Shahrabani-Gargir et al.[2004] found that the ATM gene controls IGF-I R gene expression in a DNA damage response pathway. Suzuki et al.[2004] described that IGF-I phosphorylates AMPK-alpha, a key regulator of cholesterol and fatty acid synthesis, acts in an ATM-dependent manner . We have recently demonstrated reduced levels of circulating Insulin-like growth factor-I (IGF-I) and its main binding protein 3 (IGFBP-3) in AT patients accompanied with decreased body mass index [Schubert et al.,2005]. Furthermore, apart from regulating somatic growth and metabolism, evidence suggests that the GH/IGF-I axis is involved in the regulation of brain growth, development and myelination. Moreover, GH and particularly IGF-1 have potential neuroprotective effects in different in vitro and in vivo experimental models. In addition we have recently shown that extracerebellar MRI-lesions in AT go along with deficiency of the GH/IGF-1 Axis, markedly reduced body weight, high ataxia scores and advanced age [Kieslich et al.,2009]. Supplementation with these growth hormones might overcome the progressive dystrophy and may have clinical benefits against the progression of neurodegeneration and immunodeficiency.

We found that supplementation with GH significantly increased longevity of Atm-deficient mice and improve T-cell immunity and locomotor behaviour [Schubert et al.,2009]. Surprisingly IGF-1 was not generated in the ATM deficient mice, indicating that the GH/IGF-1 signalling is impaired. Taken this into account a accurate diagnostic approach of the GH/IGF-1 axis is mandatory including a IGF-1 generation test before long term treatment either with GH or IGF-1 is justified in humans.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Ataxia Telangiectasia
  • Growth Failure
Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
Other Names:
  • Catapressan
  • Growth hormone
  • NutropinAq
  • Progynova 21 mite
  • L-Arginin_hydrochlorid-einmolar
Experimental: Growth hormone-testing (GH/IGF-1-testing)

Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.

The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days.

Intervention: Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
24
September 2012
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have a diagnosis of AT
  • Have no fusion of epiphyses/closed growth plates as determined by X-ray of left wrist and hand (special skeletal age film)
  • Be between 3 years to 18 years old and have not completed puberty
  • Consent to permit blood and/or tissue samples for storage
  • Demonstrate growth failure: height below the 10th percentile for chronological age
  • Have a primary care physician at home
  • Demonstrate growth failure, defined as growth velocity (measured as linear growth) that is less than 5% to 10% of that expected for children of the same age group, over the past 12 months
  • Willingness to remain hospitalized for several days
  • Provide evidence of serum IGF-1 level performed within the preceding 6 months and the results fall below 25% range of normal limits for age

Exclusion Criteria:

  • Have fusion of epiphyseal plates
  • Be under the age of 3 years or have reached completion of puberty
  • Have a serum IGF-1 level that is above the 25% range of normal limits for age
  • Be above the 10th percentile height for chronological age
  • Demonstrate any history of anaphylactic reaction or hypersensitivity to one of the GH formulation
  • Have any active or suspected neoplasia
  • Demonstrate signs of intracranial hypertension as evidenced by papilledema upon examination by fundoscopy
  • Have any condition that, in the investigator's opinion, places the patient at undue risk by participating in the study
  • Be unwilling to undergo testing or procedures associated with this protocol
  • Have acute or chronic infections
  • Have a hypersensitivity to one of the drugs: Clonidine hydrochlorid, Arginine hydrochlorid, Estradiol valerate, Somatropin
  • Have a presence of bradycardia, cardiac arrhythmia, have symptoms of a sick sinus syndrome
  • Suffer from depression
  • Have acute or recurrent thrombosis
  • Have acute liver diseases
Both
3 Years to 18 Years
No
Contact: Stefan Zielen, Prof. Dr. 0049-69-6301-83063 Stefan.Zielen@kgu.de
Contact: Ralf Schubert, Dr. 0049-69-6301-83611 Ralf.Schubert@kgu.de
Germany
 
NCT01052623
FRA.GHAT.2009
No
Prof. Dr. Stefan Zielen, Johann Wolfgang Goethe University Hospitals
Johann Wolfgang Goethe University Hospitals
Not Provided
Principal Investigator: Stefan Zielen, Prof. Dr. Children´s Hospital, Goethe-University
Johann Wolfgang Goethe University Hospitals
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP